Genuity Science news

Presentation entitled “Accelerating drug development through improved gene-disease association using large-scale, real-world datasets” by Robert Lumsden, PhD, Director of Business Development at the 2021 Festival of Genomics & Biodata.

Genuity Science is bringing together a distinguished panel of experts from academia, research and industry to discuss opportunities and advancements in developing better treatments for systemic lupus erythematosus (SLE).  SLE is a chronic and relapsing autoimmune disease characterized by a break-down of self-tolerance that leads to tissue inflammation and multiorgan damage.

SLE is extremely heterogeneous in nature, with the signs and symptoms varying from person to pers

Single cell sequencing has transformed our ability to discern the cellular and molecular makeup of human immune systems and tissues. The size and complexity of the data sets generated requires the application of advanced analytics and artificial intelligence to reveal the signal contained within. The marriage of scRNAseq + AI has been shown to identify rare cell populations/subtypes and provide novel insights about disease diving pathways. The ability to better 

Non-Alcoholic Steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD). The global prevalence of NAFLD is as high as one billion and is the most common cause of chronic liver disease, affecting between 80 and 100 million in the U.S., among whom nearly 25% progress to NASH. NASH is characterized by the presence of an abnormal accumulation of fat in the liver. As NASH evolves, over time it can result in fibrosis in the liver, potentially leading to cirrhosis o

Heart failure is a significant global health issue. More than half of the people who develop heart failure die within 5 years. Current treatments do not help the largest group of these patients – those with heart failure with preserved ejection fraction (HFpEF) – and have limited effectiveness for those with reduced injection fraction (HFrEF). HFpEF has been called the greatest unmet need in cardiovascular disease given the number of heart failure deaths per year and the proportio